Orgenesis (NASDAQ:ORGS – Get Free Report) and Aadi Bioscience (NASDAQ:AADI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.
Risk & Volatility
Orgenesis has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.
Profitability
This table compares Orgenesis and Aadi Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orgenesis | -3,827.81% | N/A | -130.18% |
| Aadi Bioscience | -246.06% | -71.87% | -57.28% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orgenesis | 0 | 0 | 0 | 0 | 0.00 |
| Aadi Bioscience | 0 | 5 | 0 | 0 | 2.00 |
Aadi Bioscience has a consensus price target of $1.67, suggesting a potential upside of 1.63%. Given Aadi Bioscience’s stronger consensus rating and higher probable upside, analysts clearly believe Aadi Bioscience is more favorable than Orgenesis.
Insider & Institutional Ownership
22.6% of Orgenesis shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 5.7% of Orgenesis shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Orgenesis and Aadi Bioscience”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orgenesis | $662,000.00 | 18.27 | -$55.36 million | N/A | N/A |
| Aadi Bioscience | $25.07 million | 1.62 | -$65.76 million | ($2.35) | -0.70 |
Orgenesis has higher earnings, but lower revenue than Aadi Bioscience.
Summary
Aadi Bioscience beats Orgenesis on 7 of the 11 factors compared between the two stocks.
About Orgenesis
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
About Aadi Bioscience
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
